WHO joins Merck, Europe against generic anti-parasite drug ivermectin for Covid-19
"We did see an increase in adverse effects in patients that were randomised to ivermectin," Bram Rochwerg said, citing gastrointestinal upsets and headaches.
Zurich: The World Health Organization (WHO) on Wednesday recommended against using generic anti-parasite drug ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.
The recommendation follows the European Medicines Agency's warning last week against the drug. The U.S. Food and Drug Administration (FDA) has also recommended it not be used for COVID-19.
Officials in the Bolivian city of Trinidad launched a campaign in May last year to give out free doses of ivermectin to combat the coronavirus, although the South American country's health ministry noted the lack of evidence for it as a treatment.
Ivermectin tablets have been approved for treating some worm infestations and for veterinary use in animals for parasites. Merck, an ivermectin manufacturer, has also said its analysis did not support the drug's safety and efficacy for COVID-19.
"This applies to patients with COVID-19 of any disease severity," Janet Diaz, a top WHO official for clinical care response, told reporters of the WHO recommendation, saying it was "based on very low certainty of evidence" that ivermectin helps.
The WHO's review was based on a survey of 16 trials of ivermectin involving 2,400 people, including those comparing it with hydroxychloroquine, an older malaria medicine that has been discredited as a COVID-19 treatment. There were very few placebo-controlled studies of ivermectin.
"We certainly need more data in order to make informed decisions," said Bram Rochwerg, an associate professor at Canada's McMaster University and a co-chair of the WHO panel that reviewed ivermectin.
He said the data available was sparse and likely based on chance, though he said "high quality, trustworthy trials" were still merited.
"We did see an increase in adverse effects in patients that were randomised to ivermectin," he said, citing gastrointestinal upsets and headaches.
Worldwide, he said, there are 66 trials of ivermectin registered, with 60,000 participants, so more data on its impact on the pandemic could be coming.
"We are fighting this overuse of unproven therapies - especially some of these repurposed drugs - in various parts of world without evidence of efficacy," Diaz said. "There can be more harm than any good."
